# Post Marketing Surveillance to Monitor the Safety and Efficacy of Metalyse® in Korean Patients With Acute Myocardial Infarction

> **NCT02206646** · — · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 987 (actual)

## Conditions studied

- Myocardial Infarction

## Interventions

- **DRUG:** Metalyse

## Key facts

- **NCT ID:** NCT02206646
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2003-02
- **Primary completion:** 2009-02
- **Final completion:** —
- **Target enrollment:** 987 (ACTUAL)
- **Last updated:** 2014-08-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02206646

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02206646, "Post Marketing Surveillance to Monitor the Safety and Efficacy of Metalyse® in Korean Patients With Acute Myocardial Infarction". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02206646. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*